Immunovant
IMVT
197 hedge funds and large institutions have $2.76B invested in Immunovant in 2025 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 75 increasing their positions, 54 reducing their positions, and 26 closing their positions.
403% more call options, than puts
Call options by funds: $33M | Put options by funds: $6.57M
80% more capital invested
Capital invested by funds: $1.53B → $2.76B (+$1.23B)
54% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 26
39% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 54
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
7.38% more ownership
Funds ownership: 54.6% → 61.98% (+7.4%)
6% more funds holding
Funds holding: 186 → 197 (+11)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$70.9M |
| 2 |
Morgan Stanley
New York
|
+$64.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$50.4M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$40.1M |
| 5 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$32.2M |
| 2 |
SC
Stempoint Capital
New York
|
-$21.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$13.2M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
-$10.1M |
| 5 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$9.13M |
IMVT Hedge Fund Activity: Q4 2025 in Review
197 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q4 2025, worth a combined $2.76B — up 80% from $1.53B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new IMVT positions and 26 closed out — a net gain of 14 holders — while 75 added to existing stakes and 54 trimmed.
The largest buyer was RTW Investments, opening a new position worth an estimated $70.9M. The largest seller was Point72 Asset Management, cutting an estimated $32.2M.
- 197 institutional investors held Immunovant (IMVT) as of Q4 2025, up from 186 in Q3 2025.
- Funds reported $2.76B of Immunovant stock for Q4 2025, up 80% quarter-over-quarter.
- 40 funds opened new Immunovant positions in Q4 2025 and 26 closed out, a net change of +14 holders.
- The largest Immunovant buyer in Q4 2025 was RTW Investments, an estimated $70.9M added.
- The largest Immunovant seller in Q4 2025 was Point72 Asset Management, an estimated $32.2M sold.
Based on aggregated 13F filings for Q4 2025.